{"id":176,"date":"2012-08-20T11:06:05","date_gmt":"2012-08-20T18:06:05","guid":{"rendered":"http:\/\/thefcar.org\/?page_id=176"},"modified":"2016-02-09T11:56:50","modified_gmt":"2016-02-09T19:56:50","slug":"drug-development-challanges","status":"publish","type":"page","link":"https:\/\/thefcar.org\/drug-development-challanges\/","title":{"rendered":"Drug Development Challenges"},"content":{"rendered":"<h5>Drug Development Challenges<\/h5>\n<p>Antibiotic drug development by pharmaceutical companies is extremely challenging. There are exceptional drug discovery challenges, regulatory complications and commercial issues. <strong>Discovering new antibiotics<\/strong> is inherently difficult and finding novel agents that successfully target bacteria <strong>is scientifically challenging<\/strong>. There are regulatory complexities specific to antibiotics. For example, late stage clinical trials investigating antibiotics against resistant infections require an excess number of trial participants, as not all those enrolled with be infected with the resistant strain of bacteria being targeted. There is a low return on investment for antimicrobials compared to other medicines. This limits the feasibility of antibiotic development for the pharmaceutical manufacturers. New antibiotics are used sparingly \u2013 only when patients have failed to respond to existing therapies. This significantly limits the commercial return that is needed to encourage investment in antimicrobial research and development and to fund it into the future.<\/p>\n<blockquote class=\"factoid right\"><p>There are exceptional drug discovery challenges, regulatory complications and commercial issues.<\/p><\/blockquote>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-453\" style=\"margin-bottom: 20px;\" title=\"introduction\" src=\"http:\/\/thefcar.org\/wp-content\/uploads\/2012\/08\/introduction.png\" alt=\"\" width=\"580\" height=\"565\" srcset=\"https:\/\/thefcar.org\/wp-content\/uploads\/2012\/08\/introduction.png 580w, https:\/\/thefcar.org\/wp-content\/uploads\/2012\/08\/introduction-300x292.png 300w, https:\/\/thefcar.org\/wp-content\/uploads\/2012\/08\/introduction-50x50.png 50w\" sizes=\"(max-width: 580px) 100vw, 580px\" \/><\/p>\n<p><strong>&#8220;Drug choices for the treatment of common infections are becoming increasingly limited and expensive &#8211; and, in some cases, nonexistent.&#8221;<\/strong><\/p>\n<p style=\"text-align: right;\">\u2014&#8221;A Public Health Action Plan to Combat Antimicrobial Resistance,&#8221;<br \/>\nInteragency Task Force on Antimicrobial Resistance, co-chaired by the<br \/>\nCenters for Disease Control and Prevention, the U.S. Food and Drug<br \/>\nAdministration, and the National Institutes of Health. March 2011.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Drug Development Challenges Antibiotic drug development by pharmaceutical companies is extremely challenging. There are exceptional drug discovery challenges, regulatory complications and commercial issues. Discovering new antibiotics is inherently difficult and finding novel agents that successfully target bacteria is scientifically challenging. There are regulatory complexities specific to antibiotics. For example, late stage clinical trials investigating antibiotics [&hellip;]<\/p>\n","protected":false},"author":1001009,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/pages\/176"}],"collection":[{"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/users\/1001009"}],"replies":[{"embeddable":true,"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/comments?post=176"}],"version-history":[{"count":5,"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/pages\/176\/revisions"}],"predecessor-version":[{"id":760,"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/pages\/176\/revisions\/760"}],"wp:attachment":[{"href":"https:\/\/thefcar.org\/wp-json\/wp\/v2\/media?parent=176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}